Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 127Carboplatin 125Pemetrexed 105Cisplatin 79Paclitaxel 58osimertinib 55Nivolumab 52Docetaxel 52durvalumab 48Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 35Radiosurgery 29atezolizumab 27Cetuximab 26130-nm albumin-bound paclitaxel 26Radiotherapy 22Ipilimumab 21Drug Therapy 21cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Biopsy 12lazertinib 11Radiation 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Paroxetine × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡